30.19
+5.97%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Viridian Therapeutics
From its filings with the US Securities and Exchange Commission
Viridian Therapeutics is based in Waltham, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker VRDN. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $70.8m and a net loss of $342.6m. At that date it held total assets of $899.4m and shareholders' equity of $722.2m.
We are a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. We target therapeutic areas in which current treatments leave room for improvements in efficacy, safety, and/or dosing convenience. We believe there is significant potential in these areas, for better medicines that address unmet needs, improve outcomes, and expand treatment options for patients. We aim to develop differentiated, potential best-in-class medicines that could lead to improved patient outcomes, reduced side effects, improved quality of life, and expanded market access.
Our pipeline targets validated pathways and disease-driving mechanisms in autoimmune and rare diseases. These include product candidates directed at the insulin-like growth factor 1 receptor (“IGF‑1R”) for the treatment of thyroid eye disease (“TED”), inhibitors of the neonatal Fc receptor (“FcRn”) with potential application across multiple autoimmune disorders, and a TSHR inhibitor program with potential in TED and Graves’ disease. We develop therapeutics through internal research and discovery, as well as through in-licensing opportunities that align with our strategic focus. Our capabilities span protein and antibody discovery and engineering, biologics manufacturing, nonclinical and clinical development, commercial planning, and commercialization in these therapeutic areas.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 18 Jun 2014
- Employees
- 252
- Website
- viridiantherapeutics.com ↗
- Head office
- 221 CRESCENT STREET, WALTHAM, MA, 02453
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Tomas KiselakIndependent Chairman of the Board$282,377
- Mr. Stephen MahoneyPresident, Chief Executive Officer, Director (Principal Executive Officer), since 2023$1.1m
- Mr. Seth HarmonChief Financial Officer$770,659
- Mr. Thomas BeethamChief Operating Officer$809,500
- Ms. Jennifer TousignantChief Legal Officer$4.9m
- Dr. Radhika TripuraneniChief Medical Officer
- Mr. Jeff AjerIndependent Director
- Dr. Christopher CainIndependent Director
- Dr. Sarah GheuensIndependent Director$232,664
- Ms. Arlene MorrisIndependent Director$255,020
- Ms. Jennifer MosesIndependent Director$252,664
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 59
- Environment
- 60
- Social
- 87
- Governance
- 30
- Women in the workforce
- 59%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Viridian Therapeutics develops three RNA-targeted therapeutics including VRDN-001 for thyroid eye disease treatment.
- VRDN-001 is a humanized monoclonal antibody targeting IGF-1R validated for thyroid eye disease.
- The company has initiated Phase I/II clinical trials for VRDN-001 in the US market.
Weaknesses
- Viridian Therapeutics has 252 employees with only 86 full-time staff in Waltham, Massachusetts.
- The company's product candidates VRDN-002 and VRDN-003 are still in development stages.
- Viridian Therapeutics has not yet commercialized any products as of 2014 IPO.
Opportunities
- The US market offers significant opportunities for thyroid eye disease treatments like VRDN-001.
- Viridian Therapeutics can expand its product portfolio with VRDN-002's half-life extension technology.
- The company can leverage IGF-1R target validation for future therapeutic developments.
Threats
- Viridian Therapeutics faces competition from established biopharmaceutical companies in the Health Care sector.
- The company's clinical trials for VRDN-001 may face delays or failures in the US regulatory environment.
- Viridian Therapeutics must secure additional funding to advance its three product candidates through development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.